Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg and; Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3)

Next Previous
Search
Trial Profile

An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg and; Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/telmisartan (Primary) ; Amlodipine; Telmisartan
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms TEAMSTA Severe HTN
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 24 Mar 2012 This trial is recruiting in Spain, Hungary and France.
  • 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
  • 31 Aug 2010 Results from this trial, presented at the 20th Scientific Society of Hypertension, were discussed at a briefing in Stockholm according to a Boehringer Ingelheim media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top